 WALTHAM, Mass., Sept. 30, 2021 GLOBE NEWSWIRE -- Viridian Therapeutics, Inc. NASDAQ: VRDN, a biopharmaceutical company advancing new treatments for patients suffering from serious diseases but underserved by todays therapies, announced today that two posters featuring preclinical data on VRDN-001 and VRDN-002 are scheduled to be presented at the 90th Annual Meeting of the American Thyroid Association ATA, which is being held from September 30th through October 3rd. 